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BOVINE VIRAL DIARRHEA  
VIRUS INFECTIONS 
Bovine viral diarrhea virus (BVDV) is one of the most com-
monly encountered and economically important pathogens 
of cattle in North America. Since the mid-20th century, 
BVDV has been recognized as a significant cause of disease 
of the gastrointestinal system. The impact of BVDV on re-
production was not perceived for another 30 years, when 
the occurrence of persistent infection in imunotolerant cat-
tle was described. 
BVDV infections may occur in cattle as acute illness- that 
is, bovine viral diarrhea (BVD)-or as a generally chronic 
condition-mucosal disease. When susceptible regnant cat-
tle are infected with BVDV, transplacental infections usu-
ally occur. Transplacental infections may lead to embry-
onic or fetal death and abortion, to developmental defects 
of organs, or to development of immunotolerance and es-
tablishment of persistent Infections. Acute BVDV infec-
tions contribute, through inmunosuppression, to causing 
multifactorial diseases, such as diseases of the respiratory 
and enteric tracts in sussceptible calves. 
Clinical Forms of Infection with Bovine Viral Diarrhea 
Virus 
The clinical form of BVDV infection-inapparent or severe 
BVD, reproductive failure, persistent infection, or mucosal 
disease-observed within a herd is dependent on interaction 
of several factors at the time of infection. These determin-
ing factors include the biologic properties of the virus, the 
age and stage of gestation of pregnant cattle, level of im-
munity of the herd, and the interplay of stressors.¹ 
Acute Infections 
BVD is an acute postnatal infection in seronegative, immu-
nocompetent cattle. The clinical severity of acute BVDV in-
fections is variable, but a majority of postnatal BVDV infec-
tions are inapparent. Milder forms of BVD are characterized 
by high morbidity, low mortality, a normal host immune 
response, and minimal mucosal lesions. Usual findings in-
clude pyrexia, nasal discharge, and tran- sient leukopenia. 
Viremia lasts for 3 to 10 days (acute infections with higher 
virulence isolates may result in viremia of longer duration) 
and antibody titers rise slowly for 3 months after infection.² 
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Severe acute BVD outbreaks with marked thrombocytope-
nia, hemorrhages, and high mortality rates have been asso-
ciated with infection with high-virulence BVDV isolates. 
 Acute BVDV infections contribute to causing multi- fac-
torial diseases through immunosuppression. Immunosup-
pression is mediated by suppression of immune functions 
through the lymphotropism of BVDV. BVDV lymphotro-
pism results in depletion of lymphocytes from lymphoid 
tissues. Immunosuppression due to BVDV infection en-
hances the severity of bovine rotaviral enteritis in calves, in 
addition to directly causing enteritis.³ BVDV-induced im-
munosuppression predisposes calves to development of 
naturally occurring bovine respiratory tract disease (BRD). 
Indirect effects of BVDV in causing BRD were demon-
strated in experimental bovine respira- tory syncytial virus 
(BRSV) and BVDV co-infections in which more severe re-
spiratory tract and enteric disease occurred than in infec-
tions with either virus alone. Sub- populations of lympho-
cytes were more markedly altered in peripheral blood and 
lymphoid tissues from co- infected calves than in calves in-
fected with either BRSV or BVDV alone. Co-infected calves 
had a reduction in the percentage of T lymphocytes (includ-
ing CD+ lymphocytes and CD4+ lymphocytes) in the thy-
mus and Peyer’s patches.5 An additional finding in these 
calves was more extensive pneumonia, characterized by 
caudodorsal as well as cranioventral interlobular edema, 
emphysema, and bronchopneumonia in caudal lung lobes. 
By contrast, calves infected with BRSV alone had only cra-
nioventral bronchopneumonia. 
Transplacental Infection 
Transplacental infection is likely to occur in susceptible, 
pregnant cattle infected with BVDV. The outcome of trans-
placental infection is dependent on the biologic properties 
of the infecting virus, especially the biotype of the virus, 
and the stage of gestation at the time of infection. The po-
tential outcomes of transplacental infections-embryonic or 
fetal death and abortion, developmental defects of organs, 
and development of immunotolerance with establishment 
of persistent infections-are discussed later in the chapter. 
Persistent Infection 
Fetal infection with noncytopathic BVDV can result in the 
birth of calves with persistent BVDV infection. The pri-
mary means of producing a persistently infected calf is 
through transplacental infection after a primary acute in-
fection in a pregnant cow, although persistently infected 
cows (i.e., congenitally infected) also will give birth to 
persistently infected calves. Persistently infected animals 
shed large amounts of virus and are therefore carriers and 
a primary source of exposure for susceptible cattle.6 In 
most instances they do not produce detectable antibodies 
to BVDV, because they are immunotolerant to the virus. 
Some calves with persistent infection are stunted or weak 
at birth, have poor growth rates, and die at a young age.7 
Others appear healthy and survive to maturity. The prev-
alence of cattle with persistent infection is variable; how-
ever, on the basis of sampling of randomly selected herds, 
it has been estimated that 4% of herds in the United States 
have persistently infected calves.8 Such animals are at risk 
of developing mucosal disease. 
Mucosal Disease 
Mucosal disease, associated with high mortality rates, oc-
curs sporadically (low morbidity) in cattle that usually are 
between 6 months and 2 years old but may be of any age. 
Characteristic clinical manifestations include anorexia, py-
rexia, diarrhea, loss of condition, and death.2 Gross patho-
logic lesions may include erosive or ulcerative lesions on 
the muzzle and lips, buccal mucosa, and tongue. Com-
monly, elongated ulcerative lesions occur in the mucosa of 
the esophagus. Erosions also may be found on the rumen 
pillars, reticulum, and abomasum. Enteritis may be evident 
and may vary in presentation from catarrhal to hemor-
rhagic to erosive/ulcerative. Peyer’s patches and lymphoid 
tissue in the proximal colon may be hemorrhagic.9 Thymus 
atrophy and enlarged peripheral lymph nodes are promi-
nent features. 
Biologic Properties of Bovine Viral Diarrhea Virus 
BVDV is a member of the genus Pestivirus, family Flavivir-
idae,10 which also includes border disease virus of sheep 
and hog cholera virus. Pesti viruses are small, enveloped, 
single-stranded, positive-sense RNA viruses that are anti-
genically related. 
 The host range for BVDV comprises domestic or wild 
ruminants and swine. Pestiviruses are presumed to persist 
in the environment for no more than two weeks, and are 
readily inactivated by common disinfectants. Therefore, vi-
rus transmission is primarily vertical or by inhalation or in-
gestion of material contaminated with infected body secre-
tions and excretions (saliva, oculonasal discharge, urine, 
feces, semen, uterine secretions, placenta, and amniotic 
fluid) of infected animals. 
Isolates of BVDV vary in their relative virulence poten-
tials, which accounts in part for variability in severity of le-
sions and clinical disease among different cases.” BVDV 
isolates are divided into two biotypes (groups of viruses 
with the same genetic composition) based on their abil-
ity to induce microscopically visible changes (vacuoliza-
tion and lysis) in host cells in vitro: cytopathic and noncy-
topathic. BVDV strains are divided into two genetic groups 
or genotypes-1 and 2-using gene sequencing techniques 
and cross-neutralization assays. RNA viruses, including 
BVDV, are prone to mutate; therefore, BVDV has high po-
tential to mutate in response to selective immune pressure. 
Mutation is the putative strategy used by BVDV to escape 
the host’s immune response and to persist in the cattle pop-
ulation. Antigenic diversity among field isolates has impor-
tant implications for development of protective immunity. 
Biotypes: Noncytopathic and Cytopathic 
The two biotypes of BVDV, cytopathic and noncytopathic, 
have separate biologic roles2; biotype differences are impor-
tant in disease pathogenesis. Both biotypes of BVDV infect 
cattle and cause disease, but only the noncytopathic isolates 
cause persistent infections. Isolates that have the ability to 
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cause microscopically visible changes in host cells (vacu-
olization and lysis) are assigned to the cytopathic biotype. 
Isolates lacking this capability are assigned to the noncyto-
pathic biotype. Cells infected with cytopathic BVDV have 
an 80-kilodalton (kD) polypeptide that is distinguishable 
electrophoretically from cells infected with noncytopathic 
viruses, which do not have the polypeptide.12 This 80-kD 
nonstructural viral protein apparently plays a crucial role 
in replication of cytopathic viruses. Diversity in antigenic-
ity among strains is not discretely separable. No link exists 
between biotype and antigenicity, and strains that are anti-
genically distinct overlap both biotypes, so protective im-
munity afforded by a vaccine is not dependent on the bio-
type of the vaccine virus. 
 In the laboratory, the presence of noncytopathic BVDV 
constitutes a significant quality control issue for work-
ers in diagnostic laboratories as well as for manufactur-
ers of vaccines. This is because noncytopathic BVDV iso-
lates commonly occur in commercial fetal calf sera used to 
supplement cell culture media used in cell cultures to grow 
viruses. In the diagnostic laboratory, when noncytopathic 
BVDV occurs undetected as a contaminant of cell culture, 
accuracy of diagnostic laboratory assays, such as virus iso-
lation tests and serum neutralization tests, is compromised. 
Noncytopathic BVDV contamination of modified live vi-
rus vaccines during the manufacturing process has repre-
sented a significant risk factor since these products were in-
troduced.13 The potential for contamination of cell cultures 
with noncytopathic BVDV is a continual concern, because 
between 20% and 50% of commercial fetal bovine serum 
lots are virus positive14 for both genotypes.15 Fetal bovine 
serum quality assurance procedures applied before use in 
diagnostic lab- oratory testing or in cell culture production 
systems to grow vaccine virus include rigorous virus test-
ing followed by the additional precautionary measure of ir-
radiation or chemical treatment.14 
Genotypes 
BVDV strains are divided into two genetic groups or geno-
types using gene sequencing techniques and cross- neutral-
ization assays.16,17 Genotype 1 isolates are primarily classic 
laboratory reference and vaccine strains. Genotype 2 vi-
ruses are found predominantly in fetal bovine serum, per-
sistently infected calves born to dams vaccinated against 
BVDV, and the more recently described BVDV strains as-
sociated with high mortality and acute and peracute infec-
tions involving hemorrhage. Biotype, genotype, and anti-
genic cross-reactivity vary independently,18 as do biotype, 
genotype, and pathogenicity.19 The antigenic differences 
between genotype 1 and genotype 2 isolates and the clin-
ical importance of genotype 2 BVDV isolates constitute the 
basis for the recognition that to be effective, vaccines must 
provide broad cross-protective immunity against both gen-
otype 1 and 2 isolates. 
Outcomes of Fetal Infections with Bovine  
Viral Diarrhea Virus 
BVDV enters the susceptible host primarily by the oronasal 
route and replicates in tonsils, lymphoid tissues, and epi-
thelium of the oropharynx. Phagocytic cells take up BVDV 
or virus-infected cells, or both, for transport to lymphoid 
tissues.20 Viremia is evident 2 to 4 days after exposure. Vi-
remia in a pregnant female is certain to lead to transplacen-
tal infection and fetal infection. The outcome of fetal infec-
tions with BVDV is determined primarily by the stage of 
fetal developmental at the time of infection, and by biotype 
and virulence of the infecting virus.21 The stage of devel-
opment of the evolving fetal immune system at the time of 
infection plays a major role in determining the outcome of 
infections.21 Transplacental infections are particularly dam-
aging during the first two trimesters of gestation and may 
result in persistent infections, fetal death and abortion, or 
con- genital developmental defects.22 Persistent infection in 
calves is the most significant outcome of fetal infection be-
cause of the negative effects such infection has on herd pro-
duction. Persistently infected calves are the most important 
source of virus to perpetuate disease within and between 
herds. Moreover, persistently infected calves usually have 
poor growth rates and die at a young age. Reproductive 
failure mediated by abortion and birth of calves with con-
genital abnormalities also are significant outcomes of fetal 
BVDV infections that adversely affect herd performance. 
Persistent Infections 
Persistent BVDV infections may be established if infection 
of the fetus occurs during the third or fourth month of ges-
tation before immunocompetence becomes established.21,23 
Viremia of the pregnant dam, stemming from either a per-
sistent or an acute infection, is the source of the virus that 
infects the fetus. Before infecting the fetus, BVDV replicates 
in the placenta. Persistent viremia develops as a result of 
fetal immunotolerance and failure to develop antibodies 
against the persisting virus.6 Persistently infected calves 
are carriers because they are viremic and shed virus con-
tinuously, and they may spread virus within and between 
herds. The level of viremia may decline with the develop-
ment of neutralizing antibody and become undetectable as 
the animal ages24 as a result of deterioration of highly spe-
cific immunotolerance to the persisting virus.25 Deteriora-
tion of immunotolerance, eventuating in an immune re-
sponse, may result from development of antigenic-variant 
viruses within the immunotolerant, persistently infected 
animal.25 Persistently infected calves frequently are “poor 
doers,” have reduced growth rates, are more susceptible to 
common calfhood infections of mucosal surfaces including 
pneumonia and enteritis, and are at risk of developing mu-
cosal disease.26,27 
Abortion 
BVDV infections of fetuses during the first and second tri-
mesters may cause fetal death and abortion. Third-trimes-
ter abortions also have been attributed to BVDV infection.21 
Individual isolates probably vary in their ability to cause 
abortion. The rate of abortion under field conditions is vari-
able, but abortion rates as high as 40% have been reported 
after experimental infections on day 100 of gestation.22 
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Congenital Defects 
Congenital defects may result if infection occurs during 
midgestation (100-150 days). Congenital defects associated 
with BVDV infections may involve the nervous system 
(microencephaly, cerebellar hypoplasia, hydranenceph-
aly, hydrocephalus, and hypomyelination), eye (cataracts, 
retinal degeneration, optic neuritis, and microphthal-
mia), immune system (thymic aplasia), integumentary sys-
tem (alopecia and hypotrichosis), musculoskeletal system 
(brachygnathism, growth retardation, and arthrogrypo-
sis), or respiratory system (pulmonary hypoplasia).28 The 
pathogenetic mechanisms for development of defects are 
not known. Because fetal organs and immune system (in-
flammatory response) are developing during this stage, di-
rect cell damage by viral infection and destruction of virus-
infected cells by the evolving immune system are possible 
mechanisms.21 
Late-Gestation Transplacental Infections 
The outcome of BVDV infections during late gestation (last 
trimester) is comparable with that with acute post- natal in-
fections of cattle. At this time the fetal immune system has 
developed to respond efficiently against BVDV infection. 
Consequently, transplacental infections during late gesta-
tion are not associated with a significant level of congeni-
tal defects. Third-trimester abortions have been attributed 
to BVDV infection.21 The most common outcome of infec-
tions during this period is birth of a clinically normal calf 
with high levels of precolostral antibodies.21’22 
Diagnosis of Bovine Viral Diarrhea Virus Fetal 
Infections 
Identification of Persistently Infected Cattle 
Persistently infected carrier cattle are identified in herds on 
the basis of tests conducted in a diagnostic laboratory. The 
tests include (1) the virus isolation (VI) test, (2) the immu-
nohistochemistry (IHC) test, (3) the polymerase chain reac-
tion (PCR) assay, and (4) the enzyme-linked immunosor-
bent assay (ELISA). 
Virus isolation test. The standard VI test format (mac-
rotest), a highly reliable test,7,29 is not practical for testing a 
large herd. The standard VI test may be used to test mono-
nuclear cell preparations (buffy coats) from blood sam-
ples collected in tubes with anticoagulants. The cells are 
washed to limit interference from antibodies, which reduce 
test sensitivity. An adaptation of the standard VI test is the 
immunoperoxidase microtiter plate VI assay, which is rel-
atively sensitive and specific and is designed to efficiently 
test large numbers of serum samples, such as in herd test-
ing programs.30,31 Blood is collected for virus isolation from 
calves that are 2 months of age or older, when maternal an-
tibody titers have declined, because maternal antibodies re-
duce the ability to isolate BVDV from the serum of younger 
persistently infected cattle.7,29 
Immunohistochemistry test. The IHC test is conducted 
on skin biopsy specimens (ear notches) collected from ani-
mals of any age, fixed in formalin, and submitted to the di-
agnostic laboratory.32-34 The fixed skin specimens are sec-
tioned, stained, and examined for the prescence of BVDV 
antigen. The IHC test, like the VI test, has excellent sensi-
tivity and specificity.34 Sensitivity of IHC studies is not af-
fected by the presence of maternal antibody, so calves of 
any age, including newborn calves, may be tested.34,35  
Polymerase chain reaction assay. The PCR assay may 
be used to test individual animals (serum, whole blood, or 
skin samples) or to screen entire herds by testing pooled 
samples such as bulk tank milk or pooled serum samples 
for the presence of carrier cattle.36 The BVDV PCR assay is 
highly sensitive, but a potential complication with the as-
say is lack of test specificity, so that false positive results 
are possible from nonspecific reactions with contaminating 
viral RNA (unpublished observation). It is therefore advis-
able to confirm positive BVDV PCR assay results with VI 
tests.35 
Enzyme-linked immunosorbent assay. The ELISA may 
be used to test individual blood samples for the presence 
of BVDV antigen. The antigen-capture ELISA compares 
closely with virus isolation techniques for detection of per-
sistently infected cattle using blood samples routinely sub-
mitted for BVD diagnosis. The test format is adapted to a 
microtiter plate assay, which permits efficient testing of 
large numbers of serum samples.31,37 
 Aborted Fetuses 
Diagnosis of BVDV as the cause of abortion is not unequiv-
ocal, because fetal infection may not result in abortion. 
Therefore, the presence of virus, viral antigen, or BVDV an-
tibody in an aborted fetus does not confirm that BVDV was 
the cause of abortion.28 The entire fetus should be submit-
ted to a diagnostic laboratory for complete testing because 
of the complexity of the factors to be considered in conclu-
sively establishing BVDV infection as the cause of abortion 
or, conversely, in ruling out BVDV infection as the cause 
of abortion. Diagnosis of BVDV as the cause of abortion 
is based on evidence of BVDV infection of the fetus (pres-
ence of virus, antigen, or RNA in tissues, or antibody in se-
rum or exudates), in conjunction with clinical confirmation 
of microscopic lesions, most often in fetuses aborted before 
4 months of gestation. Microscopic lesions attributable to 
fetal BVDV infection include a necrotizing inflammatory 
reaction with mononuclear cell infiltration in several tis-
sues.38 Other features may include lymphoid depletion of 
the cortex of the thymus, precocious development of sec-
ondary lymphoid tissue, and peribronchiolar lymphonod-
ular hyperplasia. The cerebellum is affected with necrosis 
and depletion of cells and infiltration of mononuclear cells. 
Microfocal lesions may be seen in the oral mucosa and in 
the skin. Skin lesions are characterized by hyperkeratosis 
and parakeratosis. BVDV antigen may be deposited in lym-
phoid tissues and in the cerebellum.9 Demonstration of ris-
ing BVDV antibody titers in paired serum samples from 
dams may be not be possible. This is because antibody ti-
ter may have already increased at the time of abortion be-
cause of the time lag from infection of the dam to abortion. 
Identification of BVDV in a fetus in the absence of lesions 
provides useful information regarding the temporal occur-
rence of BVDV within the herd. 
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Congenital Developmental Defects in Term Calves 
Diagnosis of BVDV as the cause of congenital developmen-
tal defects in term calves is based on evidence of transpla-
cental BVDV infection in combination with presence of 
characteristic clinical signs and gross or microscopic le-
sions. Evidence of transplacental BVDV infection is ob-
tained by culture of BVDV or detection of BVDV antigen 
or RNA. Antibody in serum collected from a calf before it 
has ingested colostrum also constitutes evidence of trans-
placental BVDV infection. Calves born with cerebellar hy-
poplasia have difficulty standing and exhibit a wide-based 
stance, and are ataxic. Blindness may result from congeni-
tal defects of the eye. Ophthalmic examination may be per-
formed to reveal the presence of cataracts. Calves may be 
born weak and undersized sub- sequent to fetal growth 
retardation due to BVDV infection.28 Gross lesions in-
volving the nervous system, eye, immune system, integ-
umentary system, musculoskeletal system, or respiratory 
system are described in greater detail earlier in the chap-
ter. It is prudent to exercise caution in attributing these le-
sions to BVDV without demonstrating virus or viral anti-
body, because other causes for many of these lesions exist. 
Unfortunately, the virus frequently is cleared by the time 
calves are born. Pre- suckle serum is useful for diagnostic 
applications. 
Late-Gestation Transplacental Infections 
The presence of BVDV antibody titers in serum collected 
from normal term calves before they have ingested colos-
trum indicates that infection occurred late in gestation after 
the fetus developed immunocompetence. 
Screening Herds without a History of BVDV Infection 
A herd that does not have a history of BVDV infection may 
be screened to determine if BVDV infection is active in the 
herd (i.e., determine if animals with either acute or persis-
tent infections are present). One screening approach that 
limits the expense of testing, as well as labor requirements, 
is testing for the presence of anti- bodies to BVDV in a rep-
resentative subset of nonvaccinated, sentinel cattle39 that 
are at least 8 months old.40 The presence of BVDV anti-
bodies in any of these animals indicates that one or more 
acutely or persistently infected animals are present in the 
herd.40,41 The absence of BVDV antibodies indicates that 
carrier cattle that shed virus, both acutely and persistently 
infected animals, are not present-the herd is BVDV-free. 
PCR assays of the somatic cells of bulk-tank milk is another 
approach that has been used in dairy herds to screen for 
evidence of carriers with persistent BVDV infection among 
lactating cows.36 
Prevention and Control 
The goal of a BVDV control program is to prevent fetal in-
fection to eliminate BVDV-associated reproductive losses 
and the birth of persistently infected calves. Control of 
BVDV infection is best achieved by avoiding persistently 
infected carrier cattle and acutely infected cattle, and by 
maintaining sound immunization practices. Elimination of 
persistently infected carriers from the herd is accomplished 
by testing the herd and by closing the herd to incoming an-
imals that are potentially persistently infected carriers or 
acutely infected, transient virus shedders. Identification 
and removal of persistently infected cattle require accurate 
herd-based diagnostic lab- oratory testing.42 
Detection and Removal of Persistently Infected Carrier 
Cattle 
Removal of persistently infected cattle from a herd and 
prevention of reintroduction of persistently infected cattle 
into a herd are essential herd management procedures be-
cause persistently infected cattle are the primary source of 
infection for a herd. Selection of replacement breeding cat-
tle on the basis of performance effectively eliminates some 
persistently infected cattle from the herd on the basis of 
poor growth rates. Other persistently infected animals may 
be eliminated from herds because of the shortened lifes-
pan sometimes associated with persistent infection in cat-
tle. Some persistently infected cattle, however, may have 
normal growth rates21,39 and normal lifespans and accord-
ingly be retained in the breeding herd. Consequently, the 
importance of using laboratory tests to ensure detection 
and removal of all persistently viremic cattle from a herd is 
clearly evident. Seed stock producers, especially breeders 
of purebred cattle, should be strongly encouraged to test 
their animals and remove persistently infected carrier an-
imals from their herds.35 
The greatest proportion of persistently infected animals 
in BVDV-infected herds are calves younger than 6 months 
of age.43 Initially, calves are tested, rather than dams, be-
cause if calves are tested, information about the persistent 
infection status of the calves and about that of their dams 
is obtained simultaneously. This is because persistently 
infected dams always give birth to persistently infected 
calves. IHC testing of skin biopsy specimens (ear notches) 
is recommended for this procedure. Testing and removal 
of persistently infected calves from the herd must be com-
pleted before the breeding season begins, to prevent con-
tacts of persistently infected calves with pregnant cows, so 
as to prevent transplacental infection, production of persis-
tently infected calves, and perpetuation of infection within 
the herd. In addition to testing calves, replacement heifers, 
cows not calving, bulls, and dams of any calves that test 
positive must be tested.35 
Biosecurity 
Before implementation of an extensive BVDV testing pro-
gram in a herd, the potential for re-exposure of a BVDV-
free herd to BVDV infection after completion of a persis-
tently infected carrier testing and removal program must 
be considered. Introduction of BVDV infection into a herd 
may occur by contact with cattle from other herds or with 
addition of animals to herds. Requirements for a BVDV bi-
osecurity program are that all purchased cattle be tested 
for persistent infection status or originate from a BVDV-
free herd. Purchased replacement animals should be iso-
lated and tested before being added to the herd to avoid 
introduction of acutely-infected animals. The offspring of 
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purchased pregnant replacement cattle must also be tested 
to confirm their BVDV persistent infection-free status be-
fore being added to the herd.40,44 Seed stock producers are 
obligated to maintain a BVDV-free herd by maintaining 
strict biosecurity practices, including testing of all animals 
in their herd to warrant BVDV-free status.35 
Vaccination and Immunity 
The goal of immunization is to prevent infection of target 
organs such as the fetus. This is accomplished by inducing 
both the B and T cell arms of the immune system. Free vi-
rus is inactivated by the B cell arm of the immune response, 
by neutralization of BVDV infectivity by immunoglobu-
lin, and secondarily by aggregating virions and enhancing 
clearance. Infected cells that have potential to release infec-
tious virus are eliminated by T cells.45 
Optimally, vaccines should provide broad cross-protec-
tive immunity that protects the fetus against all field strains 
of BVDV. Vaccines do provide significant protection against 
fetal infection, which will limit reproductive disease, in-
cluding production of persistently infected calves. Vaccines 
do not provide absolute fetal protection, however. Results 
of experimental challenge vaccine studies have shown that 
no BVDV vaccine can induce complete fetal protection, 
and birth of persistently infected calves in vaccinated cows 
has been reported in the field. Consequently, vaccination 
should not be relied on completely to provide protection 
against fetal infection. Management practices also should 
be implemented to identify persistently infected carrier cat-
tle and eliminate them from the herd, and to avoid expo-
sure to BVDV infection.35,46 
Modified live virus vaccines against BVDV activate sys-
temic and local, humoral and cell-mediated immune re-
sponses. Immunity induced by modified live virus vac-
cine generally is more cross-reactive than that induced 
by inactivated vaccines. Cross-reactivity is important for 
BVDV immunity because the potential for antigenic vari-
ation exists. Other advantages of modified live virus vac-
cines include longer duration of immunity and a reduced 
requirement for repeated administration of vaccine. Disad-
vantages of these vaccines are immunosuppressive proper-
ties and the potential to cause severe fetal anomalies and 
disease attributable to vaccine contamination with adventi-
tious BVDV. Another disadvantage is the potential for res-
toration of virulence of the virus during infection. Exper-
imental challenge-exposure studies have demonstrated a 
reasonable degree of protection against fetal infection us-
ing a modified live virus vaccine.47 
Inactivated vaccines are neither immunosuppressive 
nor fetopathogenic. Inactivated vaccines also offer the ad-
vantage of immunization with minimal risk of infection. In 
general, disadvantages of inactivated BVDV vaccine may 
be a need for increased frequency of administration due to 
a weaker neutralizing antibody response and shorter dura-
tion of protection. 
Timing of vaccination. The best general recommenda-
tion for control of BVDV disease includes avoiding addi-
tion of replacement animals that are persistently or tran-
siently infected, avoiding purchase of pregnant cattle, 
removal of carrier cattle from the herd, and adherence to 
a vaccination schedule based on use of both modified live 
virus and inactivated BVDV vaccines. It must be recog-
nized that live, replicating vaccines (i.e., modified live vi-
rus vaccines) have certain inherent properties (see preced-
ing discussion of benefits of modified live virus vaccines 
versus inactivated vaccines) that may enable them to in-
duce more complete protection against transplacental in-
fection. Therefore, it may be wise to recommend vaccina-
tion of unstressed, healthy heifers, isolated from pregnant 
cows, with modified live virus vaccine. All replacement 
heifers should be vaccinated twice with modified live virus 
before breeding. In non- vaccinated animals, modified live 
virus vaccines should be administered three estrous cycles 
(i.e., 2 months) before breeding. Administration of inacti-
vated vaccines to heifers before breeding should be timed 
so that maximal responses are achieved. Booster vaccina-
tions should be administered in accordance with the vac-
cine manufacturer’s recommendation. 
It may be difficult to time vaccination in a dairy herd to 
avoid use of modified live virus vaccines on premises with 
pregnant animals, because dairy cows typically are at vari-
ous stages in their reproductive cycles. Beef calves, weaned 
at 5 to 7 months of age, typically are seronegative or have 
low titers of maternal antibody at weaning time.7 Thus, 
calves should be immunized before weaning so that they 
are protected at weaning when they enter concentration 
points at which a high risk of infection exists.46 
BOVINE HERPESVIRUS-1 (INFECTIOUS BOVINE 
RHINOTRACHEITIS VIRUS) INFECTION 
Bovine herpesvirus-1 (BHV-1) is well recognized as a 
pathogen that infects the respiratory and reproductive 
tracts and also infects the fetus, potentially leading to abor-
tion. BHV-1 infects cells of the upper respiratory tract, caus-
ing rhinitis, conjunctivitis, and tracheitis. Respiratory tract 
infections with BHV-1 also may contribute to establish-
ment of bacterial bronchopneumonia by impairing host de-
fenses, such as by diminishing lung clearance mechanisms 
and by immunosuppression. If infection occurs in nonim-
mune pregnant females, systemic infection, fetal infection, 
and abortion are the likely consequences. Genital infections 
may result in development of pustular vulvovaginitis in fe-
males or balanoposthitis in males. Genital infections, char-
acterized by formation of variable numbers of small nod-
ules, vesicles, focal erosions, or ulcers visible on inflamed 
mucosal membranes, occur transiently and resolve sponta-
neously in 1 to 2 weeks. 
Important Biologic Properties of the Virus 
BHV-1 is a member of the family Herpesviridae, subfam-
ily Alphaherpesvirinae. In addition to causing a range of 
clinical diseases, it also can establish latent infections local-
ized in trigeminal and sacral ganglia.48 Latent BHV-1 can 
become reactivated under certain circumstances such as 
stress or after corticosteroid treatment.48 Vaccination with 
most modified live virus vaccines has the potential to pro-
Vi r a l Di s e a s e s  o f  t h e fe t u s   405
duce latent infections. Because of viral latency and reacti-
vation, cattle that recover from BHV-1 infections may serve 
as a source for future infection of unexposed cattle. BHV-1 
is fairly resistant to environmental influences and can sur-
vive for 5 to 13 days in warmer environments, but because 
the virion is enveloped, it is susceptible to most disinfec-
tants.49 Only one serotype of BHV-1 is recognized. 
 Infection by BHV-1 is transmitted by direct contact with 
upper respiratory, conjunctival, or genital tract mucous 
membranes. Infected animals shed virus from respiratory 
mucous membranes and secretions, or genital mucous 
membranes and secretions, for 8 to 16 days after exposure.49 
The virus is present in all fetuses aborted as the result of 
BHV-1 infection, and these fetuses can serve as a source for 
transmission of disease.50,51 Venereal trans- mission and the 
use of contaminated semen or instruments during artificial 
insemination are the primary means for transmission of 
these genital infections. BHV-1 can be isolated from the se-
men of exposed but clinically normal bulls, and this should 
be considered when exposed bulls are used either for natu-
ral breeding of un- exposed cows or as semen donors.48 
Fetal Infection and Abortions 
When BHV-1 respiratory tract infections occur in non- im-
mune pregnant females, the likely outcomes are viremia 
and subsequent fetal infection and abortion.50 Exposure of 
multiple susceptible animals in a herd can result in abor-
tion storms, with as many as 25% to 60% of cows in a herd 
aborting.51-53 Sporadic abortions also may be seen, partic-
ularly in herds with a previous history of vaccination or 
exposure. Abortions also can occur when pregnant cat-
tle are vaccinated with conventional modified live virus 
vaccines.54 
 BHV-1 abortions may occur at any gestational stage, but 
naturally occurring abortions are most common between 
4 and 8 months of gestation.51-53,55 Aborting cattle may 
be subclinically infected or exhibit overt clinical disease. 
When clinical signs are present in aborting cows, they usu-
ally manifest as respiratory tract disease or conjunctivitis.55 
Abortions are rarely seen in conjunction with infectious 
pustular vulvovaginitis.50 Abortions often do not occur for 
several weeks after appearance of clinical signs in the dam. 
The incubation period in one group of pregnant heifers, ex-
perimentally infected intravenously, ranged from 17 to 85 
days.56 The mechanism for this latent period between ma-
ternal exposure and abortion is unknown, although some 
evidence suggests that the virus may reside in the placenta 
for extended periods before infecting the fetus proper, 
without causing abortion.51 
Diagnosis of Abortion 
BHV-1 infection of the fetus results in rapid fetal death (24-
48 hours), but expulsion is delayed for up to 7 days, with 
consequent autolysis of tissue of variable degree. The pla-
centa often is retained. Gross changes in the aborted fetuses 
often are obscured by autolysis, but tiny (1- to 3-mm-diam-
eter) white-tan foci may be evident on the surface of liver 
and lung. Red-tinged serous fluid in body cavities and red 
color of fetal tissues reflecting the autolysis usually are evi-
dent. The placenta may be edematous.52 
 BHV-1 abortions can be confirmed by immunohistochem-
ical tests and microscopic examination of fetal tissues. Mi-
croscopically, scattered foci of necrosis in several organs 
may be present, which can lead to a presumptive diagno-
sis of BHV-1 abortion. In particular, foci of necrosis may be 
found in the liver, spleen, adrenal glands, lung, kidneys, 
and placental cotyledons. Herpesviral intranuclear inclu-
sions may be present in cells adjacent to necrotic foci but 
usually are masked because of autolysis. Little or no in-
flammatory cell infiltrate is found in fetal tissues, reflecting 
the rapidly lethal effects of BHV-1 fetal infection. The di-
agnosis can be confirmed either by detection of BHV-1 vi-
ral antigen or viral nucleic acid or by isolation of the virus 
from fetal tissues. Viral isolation may be difficult, depend-
ing on the degree of fetal autolysis; placental cotyledons 
are the preferred tissue for virus isolation attempts if autol-
ysis of fetal tissue is extensive.51 
 The BHV-1 antigen can be detected in cryostat tissue sec-
tion-fluorescent antibody tests (especially kidney and ad-
renal) and from paraffin-embedded formalin-fixed tis-
sues (especially liver, lung, kidney, adrenal, and placenta) 
by immunohistochemistry studies.57 Viral nucleic acid has 
been detected in aborted fetuses by in situ hybridization58 
and by PCR assay.59 Determination of BHV-1 antibody ti-
ters on paired maternal serum samples is of little help in 
diagnosing BHV-1 abortions. Most abortions occur several 
weeks after infection of the dam, so increases in antibody 
titers will have occurred before abortion. Maternal anti-
body titers indicate exposure, but without demonstration 
of rising antibody titers, it is not possible to confirm recent 
BHV-1 infection. 
Prevention and Control 
Prevention and control of BHV-1-induced abortion in 
herds are achieved primarily by implementation of sound 
biosecurity practices and by vaccination. Biosecurity prac-
tices should include control of movement of new stock into 
a breeding herd to eliminate the possible introduction of 
BHV-1 into a susceptible herd. Screening of semen used in 
artificial insemination for BHV-1 contamination and selec-
tion of seronegative donor bulls are recommended mea-
sures to prevent venereal transmission.60 Eradication pro-
grams have been established in certain European countries, 
such as Switzerland, Denmark, and the Netherlands.61 
 Vaccination commonly is practiced to prevent and control 
BHV-1 infection because of the high prevalence of BHV-
1.51 Numerous BHV-1 vaccines are commercially avail-
able and include both modified live virus and inactivated 
vaccines. Manufacturers’ recommendations should be fol-
lowed to achieve optimal immune responses and to avoid 
potential adverse effects associated with their use. Most 
modified live virus vaccines can cause all of the manifesta-
tions of BHV-1 infection in the bovine reproductive tract.62 
Because of the risk of vaccine-induced abortions and ex-
posure of susceptible dams, most modified live virus vac-
cines are not recommended for use in pregnant cattle or 
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calves suckling pregnant cows. Inactivated vaccines are 
safe for use in pregnant cattle. If modified live viruses are 
routinely employed, the timing of injections can be sched-
uled to reduce the risk of vaccine virus-induced abortion or 
transmission of virus to susceptible animals. In beef herds, 
heifers may be vaccinated before the beginning of breed-
ing season. In dairy cattle, the simplest means of reducing 
such risk is to vaccinate heifers only before breeding (4-6 
months of age, and again at 8-12 months) and to vaccinate 
postpartum heifers and cows at the time of routine post-
partum examinations. These animals are not pregnant and 
tend to be housed with like animals. Furthermore, routine 
vaccination should result in development of a “herd immu-
nity,” so that likelihood of transmission of vaccine virus to 
susceptible cattle is reduced.63 
BLUETONGUE VIRUS INFECTION 
Bluetongue virus is an orbivirus that infects cattle and 
sheep; in North America, it is transmitted by the biting 
midge, Culicoides variipennis.64 The midge becomes persis-
tently infected with bluetongue virus and may transmit vi-
rus for several weeks.65 Bluetongue virus infection of cattle 
is common in endemic areas of the world, which corre-
spond to the geographic distribution of the vector. Blue-
tongue virus is not contagious, and vertical transmission is 
not important, so perpetuation of the virus in nature is de-
pendent on continuous cycling of virus between the insect 
vector and susceptible ruminant animals.66 Cattle are con-
sidered to be natural reservoir hosts of bluetongue virus. 
Although bluetongue virus is common in cattle in endemic 
areas, bluetongue disease is rare.67 After onset of infection, 
cattle may be viremic for up to several weeks, during which 
time infected animals may act as viral amplifiers and reser-
voirs for the transmitting Culicoides vector.65 Although vi-
remias may be prolonged, they are not persistent, nor does 
this agent cause immunotolerance.67 Prolongation of vire-
mia in cattle, which facilitates infection of the insect vec-
tor, probably is the result of the strong association of blue-
tongue virus with erythrocytes, which may protect virus 
from elimination by neutralizing antibody.65 
Fetal Infection and Abortions 
Bluetongue virus fetal infection of cattle and sheep can oc-
casionally result in abortion, but teratogenesis is more com-
mon.68 Naturally occurring bluetongue virus fetal infection 
and abortion have been reported in cattle, but only in coun-
tries in which modified live virus vaccines have been used. 
Vaccine strains of bluetongue virus are the likely cause of 
naturally occurring fetal infection, because studies in preg-
nant sheep have shown that bluetongue virus crosses the 
placenta and produces fetal malformation only after the vi-
rus has been altered by adaptation to cell culture.68 
When rare fetal infections with bluetongue virus do oc-
cur, they mimic results from experimental infections. Infec-
tion of susceptible heifers or cows during early gestation 
(during the first 90-100 days of gestation) may result in fe-
tal death (by either resorption or abortion). Fetal infection 
between 75 and 100 days of gestation results in stillborn fe-
tuses or in the birth of weak calves or calves with cerebral 
malformations.69 Central nervous system abnormalities 
due to bluetongue virus infection in term calves may in-
clude hydranencephaly or cerebral cysts.67-69 Cerebral mal-
formations do not occur in fetuses infected after 150 days 
of gestation. These late-term fetal infections may have no 
effect on gestation or may result in premature births. The 
infected calves may have no visible lesions or a mild non-
suppurative encephalitis. 
Diagnostic and Control Considerations 
In most instances, infected fetuses surviving beyond midg-
estation have detectable fetal or precolostral antibodies to 
the bluetongue virus, but the virus is no longer present.67-69 
The virus is difficult to isolate, and freezing of infected tis-
sue destroys the virus. The virus is rarely if ever isolated 
from term fetuses if infection occurred before 150 days.69 
Virus may be present in the semen of seropositive bulls, 
but only when they are viremic. Bluetongue virus in semen 
is associated with the presence of contaminating erythro-
cytes or mononuclear cells that carry virus; the virus is not 
found in spermatozoa.67 International regulations prohibit 
movement of livestock and germplasm from countries har-
boring animals with bluetongue viruses to countries con-
sidered virus-free.67 U.S. livestock industries incur signif-
icant losses each year because of these trade restrictions, 
even though supporting evidence for transmission of blue-
tongue vims between countries, by either semen or em-
bryos, is lacking.67 
Vaccines are available, but owing to the rare occurrence 
of fetal infection or clinical disease in cattle, their use even 
in endemic regions seems unwarranted. Cows develop im-
munity to the infecting serotype but remain susceptible 
to infection by other serotypes.69 Because bluetongue vi-
rus is transmitted by Culicoides spp., the modified live vi-
rus in the vaccine also may be transmit- ted among animals 
by the insect vector; thus, if vaccines are used, administra-
tion of vaccines should be limited to times of the year when 
vectors are inactive.67 
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